MBX Biosciences, Inc. 13D

OrbiMed cut its MBX Biosciences stake to about 6.4% through open-market sales and frames the holding as a non-activist, opportunistic investment with standard registration rights.

OrbiMed Advisors LLC, together with OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, reports in Amendment No. 3 to its Schedule 13D that it beneficially owns 3,074,853 shares of MBX Biosciences, Inc., representing approximately 6.4% of the 48,160,096 shares outstanding, with the stake having decreased by more than 1% following a series of open-market sales by OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.; the filing describes the position as an investment holding with standard registration rights, and states that OrbiMed may buy or sell shares opportunistically but has no current activist plans regarding MBX’s governance, control, capital structure, or strategic direction.

Filing Facts

CIK

1776111

Ticker

MBX

Form

13D

Source Type

fda

Accession

0000947871-26-000776

Alert Tier

7